India’s hospital sector is experiencing rapid growth, with the hospital market valued at USD 136.6–179.8 billion in 2024 and projected to reach up to USD 348.7 billion by 2033.
Hospitals account for 80% of India’s $638 billion healthcare market in 2025, but the country faces a shortfall of 2.4 million beds for its 1.42 billion population. There are 23,582 government hospitals nationwide as of 2025.
With a market capitalization of Rs 1.08 lakh crore, the shares of Apollo Hospitals Enterprise Ltd are trading at Rs 7,570.10 per share, increasing around 1.64 percent as compared to the previous closing price of Rs 7,448.15 apiece.
Apollo is targeting ₹25,000 crore in revenue from its upcoming listed digital health platform by FY27, supported by 17–20% growth across digital, offline, and distribution segments.
The company also aims to achieve ₹1,000 crore in EBITDA by 2027 for offline pharmacy, reflecting its aggressive expansion strategy and focus on integrated healthcare delivery across multiple channels.
Looking forward to the company’s financial performance, revenue increased by 13 percent from Rs 4,944 crore in Q4FY24 to Rs 5,592 crore in Q4FY25. Further, during the same time frame, net profit increased by 60 percent from Rs 258 crore to Rs 414 crore.
Apollo’s offline health platform boasts 6,626 owned stores, services 75,000+ pharmacies, and partners with 3,000+ hospitals, covering 19,000+ pin codes with 19-minute delivery.
With 35 million+ app downloads, it offers AI-enabled diagnosis for 1,200+ conditions and 800+ symptoms, delivering 360° digital health solutions. It’s positioned as India’s leading integrated health ecosystem.
Apollo Hospitals Enterprise Limited is an India-based integrated healthcare company. The Company is engaged in the business of providing hospital services and selling pharma and wellness products through a network of pharmacies, including the operation of multidisciplinary private hospitals, clinics, diagnostic centers, and pharmacies.
Written by Abhishek Singh
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
The post Watchlist Worthy: Fundamentally strong stock with robust revenue guidance of ₹25,000 Cr appeared first on Trade Brains.